Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taldefgrobep alfa add-on study in spinal muscular atrophy
NL-OMON59233Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2023
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in spinal muscular atrophy (SMA) comparing Taldefgrobep alfa with Placebo (2 arms). Primary endpoint: Change from baseline in MFM-32 total score at Week 48. Started Apr 2023; status: active, not recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON59233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59233.